1. Preparing for Checkpoint Inhibitors in Breast Cancer

3. Understanding Immunotherapy in TNBC

4. Immunotherapy in NSCLC: CheckMate 017

5. Immunotherapy in Nonsquamous NSCLC

6. Checkpoint Inhibitors Increase Long-Term Survival, But Not Necessarily PFS

7. KEYNOTE-024: PD-1/PD-L1 Expression Levels

8. Checkpoint Inhibitors and Chemotherapy Combination Regimens

9. IMpassion130: Trial Design

10. IMpassion130: Well-Matched Baseline Characteristics

11. Primary PFS Analysis

12. Interim OS Analysis

13. PD-L1 Positivity Associated With Greater Efficacy in NSCLC

14. Hyperprogression in Response to Immune Checkpoint Inhibitor Therapy

15. Autoimmunity Induced by Immune Checkpoint Inhibitors in Patients With Cancer

16. Summary

17. Summary

18. Abbreviations

19. Abbreviations (cont)